65911-46-8

Usage

Uses

Used in Pharmaceutical Development:
2-Carbamoyl-6-nitrobenzoic Acid is used as a key intermediate in the synthesis of pharmaceuticals for its unique chemical properties and potential biological activity. It aids in the development of new drugs and contributes to the advancement of medicinal chemistry.
Used in Chemical Synthesis:
In the Chemical Synthesis Industry, 2-Carbamoyl-6-nitrobenzoic Acid is used as a building block for the creation of other chemical compounds. Its functional groups facilitate various chemical reactions, making it a versatile component in the synthesis of a wide range of products.
Used in Research Applications:
2-Carbamoyl-6-nitrobenzoic Acid is utilized as a research compound in academic and industrial laboratories. It serves as a subject of study for understanding its properties, reactivity, and potential applications in various fields of chemistry and biology.
Overall, 2-Carbamoyl-6-nitrobenzoic Acid is an important compound with a wide range of potential uses in both research and practical applications, making it a valuable asset in the fields of pharmaceutical development, chemical synthesis, and scientific research.

InChI:InChI=1/C8H6N2O5/c9-7(11)4-2-1-3-5(10(14)15)6(4)8(12)13/h1-3H,(H2,9,11)(H,12,13)

Upstream product

• 603-62-3 4-nitro-1H-isoindole-1,3(2H)-dione 
• 21606-04-2 methyl 2-carboxy-3-nitrobenzoate 
• 67-66-3 chloroform 
• 96385-50-1 3-nitrophthalamide 
• 24564-71-4 3-Nitrophthaloyl dichloride 

Downstream Products

• 603-62-3 4-nitro-1H-isoindole-1,3(2H)-dione 
• 50573-74-5 6-nitroanthranilic acid 
• 603-11-2 3-nitrophthalic acid 
• 89641-04-3 2-iodo-6-nitrobenzoic acid 
• 1015474-32-4 rac-3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione 
• 135484-76-3 Methyl 2-Bromo-6-nitrobenzoate 
• 38876-67-4 2-bromo-6-nitrobenzoic acid 
• 57113-89-0 2-amino-6-nitrobenzoic acid methylester 
• 1383609-45-7 6-(2,3-dihydroxypropoxy)-N-(2-methyl-4-oxo-3-(3-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-5-yl)picolinamide 
• 1383609-49-1 5-amino-2-methyl-3-(3-(trifluoromethyl)phenyl)quinazolin-4(3H)-one 
• 1383609-41-3 N-(2-methyl-4-oxo-3-(3-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-5-yl)pyrazine-2-carboxamide 
• 1383609-48-0 2-methyl-5-nitro-3-(3-(trifluoromethyl)phenyl)quinazolin-4(3H)-one 

Relevant academic research and scientific papers

SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES

Solid forms comprising 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)- piperidine-2,6-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.

METHODS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES

A method of identifying a subject having chronic lymphocytic leukemia (CLL) who is likely to be responsive to a treatment compound, comprising obtaining a first sample and a second sample from the subject having CLL; administering 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A) to the first sample and administering lenalidomide to the second sample; determining the level of a biomarker in the first sample and determining the level of the biomarker in the second sample; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the first sample is different from the level of the biomarker in the second sample.

METHODS FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA AND THE USE OF BIOMARKERS AS A PREDICTOR OF RESPONSIVENESS TO DRUGS

In one aspect, provided herein are methods for predicting the responsiveness of DLBCL patients to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classfiers that correlate with responsiveness to one of these drugs. In another aspect, provided herein are methods for treating a DLBCL patient determined to be responsive to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers (or output thereof) that correlate with responsiveness to one of these drugs.

CYCLING THERAPY USING 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE

Provided herein are methods of treating, preventing and/or managing cancer, including lymphoma, which comprise administering to a patient 3-(5-amino-2-methyl-4- oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cyclic therapy regimen.

COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES

Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.

METHODS FOR TREATING SOLID TUMORS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES

A method of identifying a subject having a solid tumor who is likely to be responsive to a treatment compound, comprising: administering the treatment compound to a subject having the solid tumor; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject, and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker.

METHODS OF TREATING CANCER USING 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE

no abstract published

Zn-Catalyzed Enantio- and Diastereoselective Formal [4 + 2] Cycloaddition Involving Two Electron-Deficient Partners: Asymmetric Synthesis of Piperidines from 1-Azadienes and Nitro-Alkenes

We report a catalytic asymmetric synthesis of piperidines through [4 + 2] cycloaddition of 1-azadienes and nitro-alkenes. The reaction uses earth abundant Zn as catalyst and is highly diastereo- and regioselective. A novel BOPA ligand (F-BOPA) confers high reactivity and enantioselectivity in the process. The presence of ortho substitution on the arenes adjacent to the bis(oxazolines) was found to be particularly impactful, due to limiting the undesired coordination of 1-azadiene to the Lewis acid and thus allowing the reaction to be carried out at lower temperature. A series of secondary kinetic isotope effect studies using a range of ligands implicates a stepwise mechanism for the transformation, involving an initial Michael-type addition of the imine to the nitro-alkene followed by a cyclization event. The stepwise mechanism obviates the electronic requirement inherent to a concerted mechanism, explaining the successful cycloaddition between two electron-deficient partners. (Chemical Equation Presented).

METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER

Provided herein are methods of treating, preventing and/or managing locally advanced breast cancer, including inflammatory breast cancer, which comprise administering to a patient one or more immunomodulatory compounds or enantiomers or mixtures of enantiomers thereof, or pharmaceutically acceptable salts, solvates, hydrates, co-crystals, clathrates, or polymorphs thereof.

QUINAZOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.